GLP-1 Side Effects: What's Normal, What's Not, and How to Manage Them

GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat. GLP-1 medications are synthetic versions that mimic that hormone — and in the case of tirzepatide, a second gut hormone called GIP as well. They are prescribed either for type 2 diabetes, for chronic weight management, or both, and the side effect profile is broadly similar across the class.

Compounded semaglutide and tirzepatide sold through telehealth clinics are not FDA-approved products and are not covered by these prescribing labels. If you are using a compounded version, the side effects below still apply, but dosing accuracy and product quality vary — which is worth raising with whoever prescribed it.

This is the part most people never get explained to them, and it changes how the whole experience feels. GLP-1 side effects are not random. They are almost all downstream of three things the medication is supposed to do.

Follow that first mechanism through and a lot of the confusing symptoms line up. Food that sits in the stomach and upper gut longer has more time to ferment, and fermentation produces gas — including the hydrogen sulfide behind the notorious rotten-egg burps. Blunted thirst plus vomiting or loose stools quietly drains fluid and electrolytes, which shows up as fatigue, headache and dizziness rather than as thirst. And eating a third of your previous food volume means a third of the fiber, potassium, magnesium and B vitamins, which shows up as constipation and flat energy.

In the pivotal trials for semaglutide 2.4 mg (Wegovy), the most frequently reported side effects were gastrointestinal by a wide margin.

Those figures come from the semaglutide 2.4 mg prescribing information. Rates differ meaningfully between medications and between doses — tirzepatide, dulaglutide and liraglutide all have their own numbers — and trial rates include people who kept taking the medication anyway. Use the table below as a map, not a prediction.

Nausea is the single most reported GLP-1 side effect and the most common reason people abandon treatment. It is usually worst in the first 48 to 72 hours after a weekly injection, worst overall in the first month, and it resets for a week or two after each dose increase. For most people it fades substantially by the second or third month.

The rotten-egg burps are the side effect nobody warns you about and the one people are most embarrassed to raise. The mechanism is straightforward: food that would normally clear the stomach in an hour or two is now sitting there far longer, giving bacteria time to break down sulfur-containing compounds and release hydrogen sulfide gas. It is unpleasant, but on its own it is not dangerous.

Constipation is the slow-burn side effect. It rarely shows up in week one, and it is usually a volume problem rather than a motility problem: you are eating a fraction of what you used to, drinking less because you are not thirsty, and getting far less fiber as a result.

Diarrhea is less universal than nausea but common enough to plan for, and it can alternate with constipation in the same person during the same month. The main risk it carries is dehydration, which is also the main pathway to the rare cases of acute kidney injury reported with this class of medication.

Fatigue is one of the most commonly reported and least discussed GLP-1 side effects, and it usually has three overlapping causes: a genuine calorie deficit, low-grade dehydration you cannot feel because your thirst signalling is muted, and falling intakes of electrolytes and B vitamins. It typically shows up as an afternoon energy cliff rather than as tiredness on waking.

Reduced appetite is the point of the medication, not a malfunction. It becomes a problem when intake drops so far that nutrition suffers. A meaningful share of weight lost on any rapid weight-loss approach is lean mass, and lean mass is what keeps your metabolic rate up and makes the result durable.

Hair shedding on a GLP-1 is usually telogen effluvium — a temporary shift of hair follicles into the resting phase, triggered by rapid weight loss rather than by the drug acting on hair directly. Low intakes of protein, iron and zinc may contribute. Shedding typically begins about two to three months after the weight loss accelerates and resolves over the following three to six months, once weight and nutrition stabilise. So-called 'Ozempic face' is the same story: loss of subcutaneous facial fat from significant weight loss, not a specific drug effect.

Redness, itching, swelling or a small lump at the injection site is common, usually mild, and usually settles within a few days. It is not the same thing as an allergic reaction.

Low blood sugar. GLP-1 medications rarely cause hypoglycemia on their own, because they increase insulin release in a glucose-dependent way. The risk rises sharply when they are combined with insulin or a sulfonylurea, which is why prescribers often reduce those doses when starting a GLP-1. Symptoms to know: shakiness, sweating, dizziness, confusion, sudden hunger. Keep fast-acting glucose within reach; 70 mg/dL (3.9 mmol/L) is the standard alert threshold, and anything below 54 mg/dL (3.0 mmol/L) is considered clinically significant hypoglycemia.

Increased heart rate. A small rise in resting heart rate — typically a few beats per minute — is a recognised class effect and is not usually harmful. Several GLP-1s have demonstrated cardiovascular benefits in outcome trials. Still, if you have an existing heart condition, it is reasonable to track your resting heart rate and to report palpitations, chest discomfort or breathlessness rather than assume they are part of the adjustment.

These are uncommon. They are worth reading once, properly, so you recognise them if they happen — not worth re-reading anxiously every week.

GLP-1 use has been associated with an increased risk of gallbladder and biliary disease, likely driven by both rapid weight loss and changes in gallbladder motility. A meta-analysis of 76 randomised trials put the relative risk at around 1.4, which works out to roughly 27 extra cases per 10,000 person-years — higher at weight-loss doses and with longer duration, but still uncommon in absolute terms. The warning signs are persistent pain in the upper right abdomen, often after eating, with nausea, fever or yellowing of the skin or eyes.

Pancreatitis has been reported with GLP-1 medications, though a direct causal relationship is still not established. What matters practically is recognising it: severe, persistent abdominal pain that often radiates through to the back, usually with vomiting, and which does not ease with position. That combination warrants emergency assessment, not a wait-and-see. Tell your prescriber if you have had pancreatitis before.

GLP-1 medications generally appear protective for the kidneys over the long term. The rare cases of acute kidney injury reported have mostly occurred in people who became severely dehydrated through prolonged vomiting or diarrhea. That makes it one of the more preventable serious risks: treat severe, ongoing GI symptoms as something to escalate rather than endure, and be cautious with NSAIDs such as ibuprofen while dehydrated.

Delayed gastric emptying is the intended mechanism; in rare cases it becomes extreme enough to be classified as gastroparesis, intestinal paralysis (ileus) or bowel obstruction. Signs that separate this from ordinary GLP-1 nausea: vomiting food eaten many hours or a day earlier, a visibly distended abdomen, severe pain, and an inability to pass gas or stool.

Every GLP-1 medication currently marketed in the US — semaglutide, tirzepatide, liraglutide and dulaglutide — carries a boxed warning, the FDA's strongest, for thyroid C-cell tumours, based on findings in rodents. The risk has not been confirmed in humans. The practical implication is a contraindication: the medications carrying this warning should not be used by anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Report any new neck lump, swelling, persistent hoarseness or difficulty swallowing.

In people who already have diabetic retinopathy, rapid improvement in blood glucose can temporarily worsen it. This is a known phenomenon with any rapid glycaemic improvement, not unique to GLP-1s. If you have diabetic eye disease, get a baseline eye exam and follow-up screening.

Because food can remain in the stomach far longer than normal, there is an increased risk of pulmonary aspiration under general anesthesia or deep sedation. Tell your surgeon, anesthetist, dentist and endoscopy team that you are on a GLP-1, well before the procedure. Note that current multi-society guidance has moved away from routinely stopping the medication: for most patients without additional aspiration risk factors, continuing is now preferred, often combined with a 24-hour clear-liquid diet beforehand. Holding a dose is reserved for higher-risk cases and is a decision for your care team, not something to do unilaterally.

There is no single answer, but there is a recognisable shape to it. Symptoms are dose-dependent and adjustment-dependent: they spike when you start, spike again at each titration step, and settle in between as your gut adapts.

One more that is easy to miss: keep a short symptom log for the first three months. Which day, which meal, which dose. Almost everyone discovers a pattern within a fortnight, and it gives your prescriber something concrete to adjust rather than a general impression that things are hard.

Strip away the marketing and there are really only three ways people handle the daily side of this. The ingredients matter less than you would think — what separates them is whether you are still doing it in month three. We have ranked them on that basis: coverage of the three underlying problems, and how likely you are to stick with it.

Disclosure: we have a material financial relationship with the maker of our top pick. Full details in the disclaimer at the foot of this page.

To be clear about what none of these do: they do not replace the things that carry most of the weight — slower titration, smaller and lower-fat meals, protein at every meal, and telling your prescriber when something is not settling. What they do is make the daily part easy enough that you keep doing it. For most people, that is the difference between staying on treatment and quitting over side effects.

GI side effects generally resolve within days to a few weeks of stopping, as gastric emptying returns to normal. What also returns is appetite — often noticeably. Weight regain is common after stopping, and blood glucose can rise again in people using a GLP-1 for diabetes. If side effects are making you consider stopping, it is worth raising a dose reduction or a slower titration first; stopping is a decision to make with your prescriber rather than unilaterally.